Administration

点击翻译按钮获取中文摘要

The overall goal of the University of Iowa/Mayo Clinic Lymphoma SPORE (UI/MC SPORE) Administration Core is to stimulate research in lymphoma and to expedite the translation of discoveries into new and better methods of prevention, detection, and treatment of lymphoma. The Administration Core has served well as the organizational hub of UI/MC SPORE during the initial funding period. During the next grant period it will continue to provide an organizational structure designed to efficiently coordinate the activities of the research projects, scientific cores, and developmental programs (Developmental Research Program, Career Development Program) of the UI/MC SPORE. It will also serve to enhance communication between investigators at Iowa and Mayo. The Administration Core will be responsible for coordinating the function of the SPORE committees including the Executive Committee and the External Advisory Committee. Dr. George Weiner will serve as Director of the Administration Core, and Dr. Thomas Witzig as Co-Director. Weiner and Witzig functioned well as a team during the initial funding period, and will continue to work collaboratively to provide expertise in laboratory and clinical lymphoma research. They have extensive administrative experience and are well qualified to provide leadership and direction for the UI/MC SPORE. The Administration Core will support SPORE activities by: (1) providing leadership, organizational support, and financial management for UI/MC SPORE investigators; (2) coordinating monthly videoconferences and quarterly meetings of UI/MC SPORE investigators, and the ongoing scientific review of SPORE research projects and cores, and the visits of the external advisors; (3) providing the infrastructure for the selection and support of the best and most promising projects as outlined in SPORE guidelines; (4) providing for information transfer to the scientific community via professional and public means; (5) providing the structure for the establishment and nurture of collaborations to facilitate and expand lymphoma research; (6) assuring input from patient advocates and (7) fostering trainee development.